Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer

Gabor Halmos, Andrew V Schally, Tamas Czompoly, Magdalena Krupa, Jozsef L. Varga, Zoltan Rekasi

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Antagonists of GHRH inhibit the growth of various human tumors, including prostate cancer, but the tumoral receptors mediating the antiproliferative effect of GHRH antagonists have not been clearly identified. Recently, we demonstrated that human cancer cell lines express splice variants (SVs) of receptors for GHRH, of which SV1 exhibits the greatest similarity to the pituitary GHRH receptors. In this study we investigated the expression of GHRH and SVs of GHRH receptor and the binding characteristics of the GHRH receptor isoform in 20 surgical specimens of organ-confined and locally advanced human prostatic adenocarcinomas. The mRNA expression of GHRH and SVs of GHRH receptor was investigated by RT-PCR. The affinity and density of receptors for GHRH were determined by ligand competition assays based on binding of 125I-labeled GHRH antagonist JV-1-42 to tumor membranes. Twelve of 20 tumors (60%) exhibited specific, high affinity binding for JV-1-42, with a mean dissociation constant (Kd) of 0.81 nmol/liter and a mean maximal binding capacity of 185.2 fmol/mg membrane protein. The mRNA of SV1 was detected in 13 of 20 (65%) prostate cancer specimens and was consistent with the presence of GHRH binding. RT-PCR analyses also revealed the expression of mRNA for GHRH in 13 of 15 (86%) prostatic carcinoma specimens examined. The presence of GHRH and its tumoral receptor SVs in prostate cancers suggests the possible existence of an autocrine mitogenic loop. The antitumor effects of GHRH antagonists in prostate cancer could be exerted in part by interference with this local GHRH system.

Original languageEnglish
Pages (from-to)4707-4714
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number10
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Tumors
Messenger RNA
Neoplasms
Polymerase Chain Reaction
somatotropin releasing hormone receptor
Assays
Protein Isoforms
Membrane Proteins
Adenocarcinoma
Cells
Ligands
Membranes
Carcinoma
Cell Line
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. / Halmos, Gabor; Schally, Andrew V; Czompoly, Tamas; Krupa, Magdalena; Varga, Jozsef L.; Rekasi, Zoltan.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 10, 01.10.2002, p. 4707-4714.

Research output: Contribution to journalArticle

Halmos, Gabor ; Schally, Andrew V ; Czompoly, Tamas ; Krupa, Magdalena ; Varga, Jozsef L. ; Rekasi, Zoltan. / Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 10. pp. 4707-4714.
@article{f48357c497c349c3a5d71e6666baf8e0,
title = "Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer",
abstract = "Antagonists of GHRH inhibit the growth of various human tumors, including prostate cancer, but the tumoral receptors mediating the antiproliferative effect of GHRH antagonists have not been clearly identified. Recently, we demonstrated that human cancer cell lines express splice variants (SVs) of receptors for GHRH, of which SV1 exhibits the greatest similarity to the pituitary GHRH receptors. In this study we investigated the expression of GHRH and SVs of GHRH receptor and the binding characteristics of the GHRH receptor isoform in 20 surgical specimens of organ-confined and locally advanced human prostatic adenocarcinomas. The mRNA expression of GHRH and SVs of GHRH receptor was investigated by RT-PCR. The affinity and density of receptors for GHRH were determined by ligand competition assays based on binding of 125I-labeled GHRH antagonist JV-1-42 to tumor membranes. Twelve of 20 tumors (60{\%}) exhibited specific, high affinity binding for JV-1-42, with a mean dissociation constant (Kd) of 0.81 nmol/liter and a mean maximal binding capacity of 185.2 fmol/mg membrane protein. The mRNA of SV1 was detected in 13 of 20 (65{\%}) prostate cancer specimens and was consistent with the presence of GHRH binding. RT-PCR analyses also revealed the expression of mRNA for GHRH in 13 of 15 (86{\%}) prostatic carcinoma specimens examined. The presence of GHRH and its tumoral receptor SVs in prostate cancers suggests the possible existence of an autocrine mitogenic loop. The antitumor effects of GHRH antagonists in prostate cancer could be exerted in part by interference with this local GHRH system.",
author = "Gabor Halmos and Schally, {Andrew V} and Tamas Czompoly and Magdalena Krupa and Varga, {Jozsef L.} and Zoltan Rekasi",
year = "2002",
month = "10",
day = "1",
doi = "10.1210/jc.2002-020347",
language = "English",
volume = "87",
pages = "4707--4714",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer

AU - Halmos, Gabor

AU - Schally, Andrew V

AU - Czompoly, Tamas

AU - Krupa, Magdalena

AU - Varga, Jozsef L.

AU - Rekasi, Zoltan

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Antagonists of GHRH inhibit the growth of various human tumors, including prostate cancer, but the tumoral receptors mediating the antiproliferative effect of GHRH antagonists have not been clearly identified. Recently, we demonstrated that human cancer cell lines express splice variants (SVs) of receptors for GHRH, of which SV1 exhibits the greatest similarity to the pituitary GHRH receptors. In this study we investigated the expression of GHRH and SVs of GHRH receptor and the binding characteristics of the GHRH receptor isoform in 20 surgical specimens of organ-confined and locally advanced human prostatic adenocarcinomas. The mRNA expression of GHRH and SVs of GHRH receptor was investigated by RT-PCR. The affinity and density of receptors for GHRH were determined by ligand competition assays based on binding of 125I-labeled GHRH antagonist JV-1-42 to tumor membranes. Twelve of 20 tumors (60%) exhibited specific, high affinity binding for JV-1-42, with a mean dissociation constant (Kd) of 0.81 nmol/liter and a mean maximal binding capacity of 185.2 fmol/mg membrane protein. The mRNA of SV1 was detected in 13 of 20 (65%) prostate cancer specimens and was consistent with the presence of GHRH binding. RT-PCR analyses also revealed the expression of mRNA for GHRH in 13 of 15 (86%) prostatic carcinoma specimens examined. The presence of GHRH and its tumoral receptor SVs in prostate cancers suggests the possible existence of an autocrine mitogenic loop. The antitumor effects of GHRH antagonists in prostate cancer could be exerted in part by interference with this local GHRH system.

AB - Antagonists of GHRH inhibit the growth of various human tumors, including prostate cancer, but the tumoral receptors mediating the antiproliferative effect of GHRH antagonists have not been clearly identified. Recently, we demonstrated that human cancer cell lines express splice variants (SVs) of receptors for GHRH, of which SV1 exhibits the greatest similarity to the pituitary GHRH receptors. In this study we investigated the expression of GHRH and SVs of GHRH receptor and the binding characteristics of the GHRH receptor isoform in 20 surgical specimens of organ-confined and locally advanced human prostatic adenocarcinomas. The mRNA expression of GHRH and SVs of GHRH receptor was investigated by RT-PCR. The affinity and density of receptors for GHRH were determined by ligand competition assays based on binding of 125I-labeled GHRH antagonist JV-1-42 to tumor membranes. Twelve of 20 tumors (60%) exhibited specific, high affinity binding for JV-1-42, with a mean dissociation constant (Kd) of 0.81 nmol/liter and a mean maximal binding capacity of 185.2 fmol/mg membrane protein. The mRNA of SV1 was detected in 13 of 20 (65%) prostate cancer specimens and was consistent with the presence of GHRH binding. RT-PCR analyses also revealed the expression of mRNA for GHRH in 13 of 15 (86%) prostatic carcinoma specimens examined. The presence of GHRH and its tumoral receptor SVs in prostate cancers suggests the possible existence of an autocrine mitogenic loop. The antitumor effects of GHRH antagonists in prostate cancer could be exerted in part by interference with this local GHRH system.

UR - http://www.scopus.com/inward/record.url?scp=0036776259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776259&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-020347

DO - 10.1210/jc.2002-020347

M3 - Article

C2 - 12364462

AN - SCOPUS:0036776259

VL - 87

SP - 4707

EP - 4714

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -